SignalXSignalX

VRDN Viridian Therapeutics, Inc.\DE

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Viridian Therapeutics, Inc.\DE Overview

Viridian Therapeutics, Inc.\DE (VRDN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Potential failure to meet DRI Purchase and Sale Agreement milestones after October 2025, risking up to $245M in milestone payments
  • • Updated clinical development risk: FDA may require additional patients beyond 300 in safety databases for veligrotug and VRDN-003, potentially delaying approvals
+3 more insights

Get deeper insights on Viridian Therapeutics, Inc.\DE

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.